Significant morbidity and mortality are associated with the Conditioning therapy needed for postnatal bone marrow transplantation (BMT) for inherited diseases. This could be eliminated with hematopoietic stem cell (HSC) transplantation in utero, when the immunoincompetence of the fetus permits engraftment without the need for immunosuppressive therapy. We have established an in utero (day 11 t o day 13) model of HSC transplantation in nondefective, allogeneic major histocompatibility complex (MHC)-mismatched mice. Donor cells were from pooled fetal livers of C57BL/6 (H2b, GPI-lb) mice. Engraftment was tested by quantitative polymerase chain reaction (PCR) for the Y chromosome in female recipients (with 0.0001% sensitivity). Eight percent (3 of 36) of allogeneic mismatched (Balb-c, H-2d) recipients and 25% (3 of 12) of congenic (C57B116, GPI-la) recipients showed durable engraftment (male donor cells detected beyond 20 weeks of age) based on analysis of peripheral blood leukocytes (P > .08). When spleen and liver were analyzed, 51% (17 of 33) of allogeneic recipients and 50% (6 of 12) of congenic recipients showed durable engraftment ( P > .3).
The percent donor cells that durably engrafted varied from as low as 0.0001% in spleen and liver t o as high as 0.6% in peripheral blood. Postnatal boosting with a single dose of allogeneic MHC-mismatched donor cells in a tolerant, engrafted mouse resulted in a significant increase in donor cells in the peripheral blood from 0.29' 0 pre-boost t o 5% 6 RANSPLANTATION OF bone marrow-derived hematopoietic stem cells (HSC) is currently used to treat a variety of childhood stem cell defects and inherited dise a s e~. "~ However, the use of bone marrow transplantation (BMT) is limited by toxic pre-BMT conditioning with chemotherapy and, sometimes, radiation therapy, limited HLAmatched donor availability, risk of graft-versus-host disease (GVHD), and the fact that many children are already severely compromised by their underlying disease by the time they are candidates for a postnatal BMT. 4 Performing the transplant in utero, before immunocompetence is well established, may circumvent the need for conditioning treatment and provide normal circulating cells before disease progression. Also, early in gestation, major histocompatibility complex (MHC) differences between donor and recipient may not be as important as they are postnatally, thus permitting the use of alternative MHC-mismatched sources of HSC. Even partial restoration of normal cell lineages by donor HSC may ameliorate or eliminate clinical manifestations of some diseases4 Alternatively, establishment of low-level chimerism with MHC-mismatched cells in utero could render the patient tolerant to subsequent postnatal therapeutic transplantation without the need for standard conditioning therapy.
Previous studies in murine models have shown the feasibility of in utero transplantation and creation of durable chimerism in W and W4'-defective mice, in which there is a selective advantage for engraftment of normal donor stem cells."" There have been only a few studies of in utero T months after the boost. There was no evidence of engraftment in nontolerant mice after the postnatal boost with a similar dose of donor cells. Twenty-two allogeneic recipients were evaluated for donor skin graft acceptance at 6 t o 12 months of age. Three mice with engraftment in blood and/or tissue permanently accepted donor skin grafts, one of them with donor cells detectable only in the liver. Six additional mice that showed prolonged skin graft acceptance had no evidence of durable engraftment in the blood but were engrafted in the liver and/or spleen. The degree of engraftment in tolerant mice was low (50.1% donor cells). We conclude that at an early gestational age in nondefective mice (1) high rates of durable engraftment are achievable, although the degree of engraftment is usually low (less than 1%); (2) the percent of donor cells in the peripheral blood may be increased by a postnatal boost of donor cells in tolerant animals without conditioning therapy; (3) MHC appears t o have little influence on engraftment efficiency at an early gestational age; (4) a very small number of circulating donor cells in the blood or the tissues is sufficient for the induction and maintenance of tolerance, and (5) the presence of donor cells in the circulating blood is not necessary for prolonged skin graft acceptance or maintenance of permanent skin graft acceptance. 0 1995 by The American Society of Hematology.
transplantation in nondefective recipients, the results of which suggest a transient and low rate of engraftment.".13 However, these previous studies used a relatively insensitive method for detecting donor cells. Using a highly sensitive and quantitative polymerase chain reaction (PCR) assay, we now report the establishment of a nondefective mouse model of in utero transplantation with significant, durable engraftment at an early gestational age of MHC-mismatched HSC, in which a selective advantage for donor cells does not exist. We have evaluated engraftment in a variety of tissues and correlated the degree of engraftment with induction of tolerance by donor skin graft acceptance. We have boosted postnatally tolerant and nontolerant animals with donor allogeneic cells without any conditioning therapy to explore a new strategy for increasing the donor cell population in the peripheral blood.
MATERIALS AND METHODS
Mice. Mice were housed in the Animal Care Facility at University of California San Francisco (UCSF: San Francisco, CA) under standard federal guidelines and with the approval of the UCSF Committee on Animal Research. For time-dated pregnancies, we used a method of estrous suppression in females by crowding them, with subsequent estrous acceleration by caging them with males. The day on which the vaginal plug was identified was designated as day 0. For the congenic recipients, C57BY6 (GPI-la, Thyl.1, H-2b) breeding pairs were purchased from Jackson Laboratory (Bar Harbor, ME). Allogeneic mismatched recipients, Balb-c (GPI-la, H-2d, Thyl.2) and donors CS7B1/6 (GPI-lb, H-2b, Thy1.2), were purchased from Simonsen Laboratory (Gilroy, CA).
Fetal liver preparation. Pregnant females were killed by cervical dislocation at 15 to 16 days of gestation. All subsequent handling was done under sterile conditions. The uterine horns were removed and dissected in phosphate-buffered saline (PBS; UCSF Culture Facility, San Francisco, CA). Fetuses were separated from the uterine decidua and extraembryonic membranes and transferred to 100 x IS-mm petri dishes filled with PBS. Fetal livers were removed, and S to 10 livers were placed in I to 2 mL RPMI 1640 medium (GIBCO BRL, Grand Island, CA) with 15% fetal calf serum (FCS). A cell suspension was prepared by repeated pipetting of the livers through a 23-gauge needle attached to a I-mL pipette. The mononuclear cells were separated by centrifugation at 500 g for 20 minutes and filtered through a Nitex filter with a 41-pm pore size (Nitex HC3-41; Tekto, Elmsford, NY). The final viable cell count (usually greater than 80%) was performed using trypan blue exclusion, and the final cell suspension was prepared in PBS/I5% FCS at a concentration of 1 X 108/cc. The cell suspension was used for transplant within 4 hours of preparation.
in utero transplants. Micropipettes were prepared from capillaries using a Brown and Flaming micropipette puller (T-87; Sutter Instruments, San Rafael, CA). The end of the needle was cut under a microscope with jeweler's forceps, and the tip was sharpened on a micro-grinding wheel. Pregnant (1 1 to 13 days) mice were anesthesized with ether inhalation and Nembutol IP (15 mgkg). The uterus was exposed through a vertical laparotomy incision. The tip of the micropipette was inserted through the uterine wall into each fetus intraperitoneally (IP) in 12 to 13-day-old fetuses and transplacentally (TP) in 1 l-day-old fetuses as described by Fleischman and mint^.^ Each injection consisted of S X IO5 viable fetal liver cells in S pL of PBS. Quiet, undisturbed housing was essential for successful survival.
Preliminary trials with India ink demonstrated that microinjection into the placenta at 11 days and into the peritoneal cavity at 12 to 13 days could be reliably performed, with the injected material rapidly appearing in the fetal circulation. Days I1 to 13 were chosen as the gestational a$e for experimental injection of cells because the placenta has by then attained a sufficient size and hematopoiesis has already started in the liver, which allowed its visualization during intraperitoneal injections. A few fetuses were dissected 1, 2, and 6 hours after injection, and livers were prepared for donor DNA analysis. Donor cells were found in the liver at each of these time points, suggesting that absorption of donor cells into the portal circulation occurred quite rapidly after intraperitoneal injection (data not shown).
Collection of blood and tissues. Peripheral blood was obtained by incision of the tail tip with a scalpel; and blood was collected into microhematocrit heparinized capillary tubes. Bone marrow was sterilely obtained by flushing femurs and tibias using a 20-gauge needle and l-mL disposable syringe with RPMI 1640 and lS% FCS. The donors of the livers and spleens were anesthesized with Metofane. The skin was washed with 70% alcohol, and a small, transverse abdominal incision was made. Pieces (3 X 3 mm) of liver and spleen were cut using microscissors and placed in a petri dish with PBS. Hemostasis was obtained by applying pressure with a sterile gauze for a few minutes. The skin was sutured using S-0 Dexon sutures (DG, Manati, Puerto Rico). A cell suspension from the tissues was made by grinding them between frosted ends of microscope slides (Fisherbrand; Fisher Scientific, Pittsburgh, PA), and cell counts were performed. The average number of cells in representative pieces of liver and spleen was used for calculating the percent donor cells by quantitative PCR. After each tissue and blood collection, the instruments (microscissors, scalpel, forceps) were thoroughly cleaned with 70% alcohol to avoid crosscontamination. To demonstrate that the procedures we used did not create crosscontamination, we collected blood, liver, spleen, and bone marrow from IO nontransplanted female mice. We also intentionally exposed the instruments to male mouse tissue followed by cleaning with 70% alcohol before collecting the female tissues. These female samples were then tested for the presence of the Y chromosome. In no case was there a false-positive signal.
Glucose phosphate isomerase (GP,) isoenzyme detection. We used a GP1 assay previously reported by Chapman et al. ' 4 Blood was diluted 1:40 with sterile water, loaded onto a cellulose acetate gel, and electrophoresed for 40 minutes at 220 V. The staining solution consisted of IS pg substrate, fructose-6-phosphate (loo/ mL; Sigma Scientific, St Louis, MO; F-3627), I O pL cofactor, nicotinamide adenine dinucleotide phosphate (NADP; I O mg/mL), 50 pL 2 molL Tris pH 8, 20 pL MgCIZ or MgAc (1 moYL stock), 100 pL methylthiazolium tetrazolium ( I O mg/mL; Sigma M-2128), 80 pL phenazine methosulphate (2.5 mg/mL, Sigma), and 70 pL glucose 6 phosphate dehydrogenase (G6PD; 140 U/mL). It was poured onto the gel and incubated at room temperature for 20 minutes. The plates were then fixed in 5% acetic acid, and the presence of GPIla and GPI-Ib bands were determined by visual inspection.
DNA preparation andprocessing. To quantitatively assay leukocytes from recipient blood samples, 100 pL of whole blood was subjected to red blood cell (RBC) lysing using 100 pL saponin lysis buffer (0.4% saponin [ICN Biochemicals, Cleveland, OH] in 0.5% NaCI) within 24 hours of the blood collection.'' After a 5-minute incubation at room temperature with intermittent mixing, the tube was centrifuged at 600 g for S minutes in a microcentrifuge. The leukocyte pellet was then washed twice with 200 pL PCR solution A (100 mmoVL KCI, 10 mmol/L Tris pH 8.3, 2.5 mmol/L MgCI?), followed by re-suspension in 50 pL of PCR solution A and freezing. DNA was prepared by adding SO pL of PCR lysis solution B ( 1 0 mmoVL Tris pH 8.3, 2.5 mmom MgCI2, 1 % Tween-20, NP40,0.4 mg/mL proteinase K) to each leukocyte pellet and incubating at 60°C for 1.5 hours with vortexing every 20 minutes, followed by 9S°C for 2 hours. The DNA lysates were then tested in duplicate, in a single PCRhybridization polyacrylamide gel electrophoresis (PAGE)/autoradiography run along with analysis of a duplicate standard dilution series.
Sequencespecific PCR and quanritarion of donor cells. A quantitative, allele-specific polymerase chain reaction (QAS-PCR) assay directed at murine Y chromosome-specific sequences was used, as previously described. 16 Briefly, 25 pL of DNA lysate was added to SO pL of the PCR mixture (100 mmoIlL KCI, 20 mmoUL Tris HCI pH 8.3,2.5 mmol/L MgCIZ, 0.2% gelatin, I pmoUpL of each primer, 0.04 UIpL Taq polymerase). After amplification, the preparations were hybridized at 95°C for 5 minutes and 60°C for S minutes with For personal use only. on September 24, 2017. by guest www.bloodjournal.org From Abbreviation: NT, not tested.
P3*-labeled oligonucleotide probes. Specific amplified products were separated on 6% polyacrylamide slab gels at 12.5 V/cm. The gel was exposed to XAR-5 autoradiographic film (Eastman Kodak, Rochester, NY) with an enhancing screen for 2 hours and overnight at room temperature. Duplicate standard curves composed of DNA lysates derived from I0-fold serial dilutions of donor (male) in recipient (female) cells (IO3, lo2, lo', 10' ) were analyzed in parallel with the samples and used to interpolate donor cell concentration. Autoradiographs were analyzed using the Millipore BioImage Electrophoresis Analyzer with Whole Band Analyzer application software (Millipore, Ann Arbor, MI). Image analysis was performed on a film exposure (2 hours or overnight) that was within the linear range of the corresponding standard curve on that film. Values from duplicate determinations were averaged. The autoradiograph image was first acquired by the computer using a transmissive scanner (Howtek Scanmaster 3+; Bioimage, Ann Arbor, MI). After manual input of gel margins, numbers of lanes per gel, and numbers of gels per image, the program finds the bands corresponding to amplified DNA and places lane indicators. The program then draws boundaries around the bands and measures the intensity of each band width, subtracting background intensity of that lane. Internal concentration standards are assigned to the bands resulting from the standard curve amplifications. The program then compares unknown samples against the standard curve samples using linear interpolation to determine the concentration of the unknown through a formula taking into account the area and intensity of each band. The reproducibility of the image analysis system was assessed by replicate Skin graft placement. Donor ventral trunk and ear skin were used. The donors were anesthetized with Metofane and killed by cervical dislocation. The ears were removed, split into two identical pieces and placed in a petri dish with PBS. For full thickness skin grafts, the trunk was shaved with electric clippers and drenched in 70% alcohol. The skin was cut circumferentially at the level of the shoulder joint and hip joint, using a scalpel or scissors, and then peeled off using a watchmaker's forceps and placed in a petri dish with PBS. Areas with new hair growth and pigmented nevi as well as dorsal skin were removed. The fat and subcutaneous tissue from the remaining ventral skin were scraped with the curved edge of the watchmaker's forceps, and the skin was cut into grafts of uniform size and shape. The recipient mice were anesthetized with Metofane, and the skin was shaved and washed with 70% alcohol. Using watchmaker's forceps, the skin was cut as superficially as possible from the point next to the spine at the level of the top of the scapula. An inferior cut was created and the square of skin to be removed was completed with two additional cuts. The skin was then carefully peeled from the graft bed, minimizing disruption of the vascular supply. The ventral skin or ear graft was placed on the graft bed so the graft did not overlap with the surrounding normal skin. The entire graft bed and a small margin of surrounding tissue was covered with a double-thickness square of Vaseline gauze (Sherwood Medical, St Louis, MO), and the wound was covered with a ' /' -in sheer Band-Aid (Johnson & Johnson, Arlington, TX). After 7 days, the Band-Aid was removed. Grafts were scored daily. 
RESULTS

Outcome.
The average survival rate following in utero transplantation was 30% and, in some groups of animals, was as high as 60%. Deaths were a result of in utero reabsorption of the fetuses after surgery. A small number (less than 1 %) of newborns were killed by the mothers after delivery. There was no difference in the survival rate between the allogeneic and congenic recipients. The total number of surviving newborns in the allogeneic MHC-mismatched group was 75, with 37 females available for study of engraftment of male cells. There were 46 survivors in the congenic group, with 12 females available for comparable engraftment studies. Newborns that survived the first 2 weeks of life lived a normal life span. Occasional deaths were related to oversedation with anesthesia during the procedures and/or old age. Animals had normal-appearing skin, thrived well, and had a good activity level. No signs of GVHD, such as runting, weight loss, hunched posture, and skin lesions, were observed at any time point, and so the longest living animals are now more than 2 years old. Because of this lack of clinical symptoms of GVHD, the histologic examination of the tissues for GVHD was not performed. Engmfrrnent. Mice were evaluated at various intervals beginning at 1 to 2 weeks of age. Initially, all mice (including males, n = 75) were tested every 4 weeks for engraftment in the peripheral blood by GP1 only, and evidence of donor cells was documented in two mice (mice 45 and 56). Because the sensitivity of the GP1 assay is approximately I%, we switched to a PCR assay using a murine probe for the Y chromosome, which has a sensitivity of 0.0001%. Because this latter test for engraftment was implemented later, 14 older mice in the female recipient group were tested for the first time by PCR at 4 to 5 months of age. It is, therefore, possible that some of these mice had donor cells present during the first 4 to S months of life that subsequently disappeared from the circulation. As the newborn colony was large (37 females; 75 total), blood draws were performed on the whole colony every 1 to 2 months. Each mouse had 4 to I O engraftment tests performed. In addition, IO control, nontransplanted female Balb-c mice were tested for the presence of the Y chromosome in the blood, liver, spleen, and bone marrow; there were no false-positive PCR amplifications.
Tissues (liver and spleen) were obtained in vivo at one
For
the whole colony (n = 75) and the GP1 assay was performed on each of them. The age of tissue harvest for each recipient mouse was carefully documented (22 to 44 weeks). Biopsies were performed by laparotomy, and only one harvest in vivo could be performed for each mouse. Bone marrows were obtained only on deceased animals and, if possible, spleens and livers were harvested for additional repeat PCR testing; the results were reproducible in all cases. Durable engraftment was defined as donor cells present beyond 20 weeks of age in any tissue or blood. The results of durable engraftment of male donor HSC in the peripheral blood and tissues of female allogeneic and congenic recipients are shown in Table 1 . The engraftment rate in blood was low, and no significant difference was seen between the congenic (3 of 12) and allogeneic (3 of 37) recipient groups ( P > .08). Donor cells were detected transiently in the blood before 20 weeks of age in 6 of 12 (50%) congenic recipients and 4 of 37 (10%) allogeneic recipients ( P < .05). In 9 of these 10 animals in which donor cells were transiently present in the peripheral blood, durable engraftment was seen in the liver or the spleen.
When the livers were evaluated, there was a significantly higher engraftment rate in allogeneic compared with congenic recipients: 14 of 32 (43%) and none of seven (O%), respectively ( P < .05). The opposite was seen when the spleens were evaluated; that is, 3 of 32 (9%) and five of eight (62%) in the allogeneic and congenic animals, respectively, had detectable donor cells ( P < .02). The combined engraftment rate in these tissues (livers or spleens) was similar in both groups: 17 of 33 (51%) in allogeneic and five of eight (62%) in congenic recipients ( P > .3). When engraftment in blood was considered in addition to liver or spleen, there also was no difference between the two groups: 17 of 37 (45%) and 6 of 12 (SO%), respectively ( P > .3).
Bone mamw was tested postmortem in allogeneic recipients only, and in eight animals tested after 20 weeks of age (median age, 28 weeks; range, 22 to 55 weeks), seven had evidence of engraftment. Interestingly, in five of these mice in which donor cells were present in the marrow, donor cells were not detected in liver, spleen, or blood. One mouse who was engrafted in the bone marrow showed evidence of donor cells in the peripheral blood at 6 weeks of age only. Another mouse had a very low level of donor cells in the liver when tested at 36 weeks.
The kinetics of engraftment in peripheral blood and tissues of representative mice are shown in Fig 1. Some animals (eg, mouse 35) never showed evidence of engraftment in the blood, spleen, or liver, while others (eg, mice 40, 43, 63, and 71) showed early engraftment with subsequent loss of donor cells, and some (eg, mice 45, 56, and 57) had donor cells present in the peripheral blood during each test. Mouse 57 had no evidence of donor cells in the peripheral blood when tested at 52 weeks. Three mice that were durably engrafted in the blood had donor cells present in the liver as well. Additionally, mouse 63 had donor cells detected in the spleen at 22 weeks of age and in the thymus and bone marrow (tested postmortem) at 55 weeks of age.
Degree of engraftment. The QAS-PCR assay was used to estimate the degree of engraftment (ie, percent of donor cells) in the blood, liver, spleen, and bone mamw (Fig 2) . The results underestimate the actual percent donor cells by approximately 50% because the pooled fetal livers represented a mixture of male and female cells. Because we'did not assay the individual donor preparations for the specific mix of male-to-female cells, we have not adjusted our results. In mouse 45, the degree of engraftment was higher in the blood than in the liver, and no engraftment was detected in the spleen. In mice 56 and 71, there was a progressive decrease in donor cell numbers in the blood with each subsequent test. Mouse 71 lost donor cells in the blood by 20 weeks, but had donor cells detected in the liver at 24 weeks of age.
The percent of donor cells in the blood, bone marrow, and tissues of the congenic and allogeneic recipients is shown in Fig 3. There was no significant difference in the percent donor cells between congenic and allogeneic recipients (data not shown), and results were combined. In most animals (8 of 10) with donor cells transiently appearing in the blood, the percent of donor cells was relatively low (0.001% to 0.005%) compared with those with donor cells that persisted in the peripheral blood (0.004% to 0.6%); however, the difference was not statistically significant ( P > .3). The degree of engraftment in the tissues was very low, with a range of 0.0001% to 0.08%. The median degree of engraftment in the liver was 0.0003%, and in the spleen, 0.0001%. The degrees of engraftment in two allogeneic bone marrow samples were in the range seen for peripheral blood (Fig 2C) .
Engraftment of donor erythrocytes was tested in all (n = 75) allogeneic recipients by assaying for donor GP1 isoenzyme activity, which has a sensitivity of approximately 1 %. Only two animals (mice 45 and 56) with the highest degree of engraftment by PCR had detectable donor (GPI-I b) activity (Fig 4) . Positive bands were visually compared with control bands (10%. S%, and I %). and the highest percent of detected donor cells i n mouse 45 was approximately l%. The GP1 test was performed on the whole blood and separated packed erythrocytes (PRRC) and was positive in both. with almost identical band intensities, suggesting that detected donor cells had their origin predominantly in the PRRC population. The degree of engraftment of nucleated cells in mouse 45 as measured by PCR was 0.6% (approximately 1.2% when the mixture of male and female cells in the donor inoculum is taken into account), which is comparable with what was found by GP1 assay in erythrocytes.
Tolercrr~ce ir~riuctio~~. The relationship of engraftment in the peripheral blood and tissues to permanent or prolonged tolerance induction is shown in Table 2 . Twenty-two allogeneic female recipients (Balb-c) were grafted with syngeneic (Balb-c). donor (CS7BL/6), and third party (C3H) skin grafts at 6 to 12 months of age. Control mice rejected allograft and third party skin grafts at a median time of 14 days (range, 12 to 16 days), and accepted syngeneic skin grafts indefinitely. Three groups of skin graft recipients were identified: those in which donor skin grafts were accepted indefinitely, those in which skin grafts were rejected within 2 weeks, and those with prolonged acceptance at S to 6 weeks after placement. followed by rqjection. Photographs of syngeneic, allogeneic (donor) and third party skin grafts of two tolerant mice are shown in Fig S. Thirteen nonengrafted (ie, no donor cells detected in the blood or tissues at any time point evaluated) mice rqjected skin grafts within 2 weeks. Three mice, all with engraftment in the blood and/or tissues. accepted donor skin grafts permanently, and six mice, with donor cells in the tissues only (liver, spleen; and/or bone marrow). showed prolonged skin graft acceptance. Of these nine mice with prolonged or permanent skin graft acceptance, eight were durably engrafted in the liver, one of which had additional engraftment in the spleen. One of these nine recipients died secondarily to anesthesia overdose and, when tested postmortem at SS weeks of age, showed engraftment in the thymus and bone marrow. Two of three mice with permanent donor skin graft acceptance had durable engraftment in the blood, one of which was engrafted in the liver and the second in the liver and the spleen. The third mouse was durably engrafted in the liver only (bone marrow and thymus not tested).
The relationship of the degree of engraftment in the blood and tissues and tolerance induction in selected mice is shown in Fig 6. In mouse 71, the skin graft was permanently accepted. even after donor cells disappeared from the blood shortly after the graft placement. The only durably engrafted site (bone marrow and thymus not evaluated) was the liver, with 0.02% donor cells detected 1 1 weeks after skin grafting. Mouse S7 accepted a donor skin graft for 6 weeks, with O.OOS% donor cells in the liver IS weeks before grafting and less than 0.01% donor cells in the blood during the grafting. Two other mice (mice 45 and 56) with permanent skin graft acceptance had less than 0.1 % donor cells in the blood during the graft placement. One of these mice (mouse 56) had a decrease in donor cells to 0.03% at 7 weeks after the graft placement. and continued to be tolerant to the donor skin graft. Another mouse (mouse 4 3 , who maintains a donor skin graft S2 weeks after placement, persists in having donor cells in the blood. In six allogeneic recipients who showed prolonged skin graft acceptance with no evidence of engraftment in the blood but donor cells in the tissues. the degree of engraftment in the tissues was generally less than 0.0003% (only one recipient had 0.001%).
Postnntnl hoosts. To test a strategy for increasing the percent of donor cells in the peripheral blood after in utero transplantation, we injected donor allogeneic MHC-mismatched fetal liver cells into tolerant, nontolerant, and control mice. Mouse 45, which was durably engrafted in the peripheral blood and the liver and was permanently tolerant by skin graft acceptance, was transplanted with 1 X 10" donor fetal liver cells at 44 weeks of age without the use of
Examples of syngeneic (SYN) and allogeneic (ALLO) skin grafts in representative tolerant mice. Arrow indicates the site of third party (C3HIHeN) skin grafting, in which graft was rejected. All grafts for an individual mouse were performed at the same time point. The left side of the dorsal trunk surface was used for allogeneic and third party skin grafting, and the right side of dorsal trunk was used for syngeneic skin grafts.
any conditioning therapy. This mouse showed a fivefold and 2 weeks and at 1, 2, 6, and 9 months after,a postnatal boost 25-fold increase of donor cells in the peripheral blood 3 and (Fig 7) . Mouse 6, which had no evidence of engraftment at 6 months after boost, respectively (Figs 2A and 7) . Mouse any time and rejected the donor skin graft, similarly did not 40, which had a transient presence of donor cells in the show any evidence of donor cells at 2 weeks and at I , 2, 7, peripheral blood at I8 weeks of age with subsequent negative and 8 months after the boost (Fig 7) . peripheral circulation at 2 weeks and at 1, 2, and 6 months posttransplant (data not shown).
DISCUSSION
Using a highly sensitive quantitative PCR assay, we have demonstrated for the first time durable engraftment of allogeneic MHC-mismatched HSC in a large percent of nondefective recipient mice after in utero transplantation. Most studies of in utero HSC transplantation in murine models have used W" 5-10 or W4' ' I anemic recipients, in which defective stem cell proliferation allowed preferential engraftment of donor stem cells and correction of congenital anemia. With fetal liver as the source of donor cells, the extent and durability of the graft was shown to be related to the severity of anemia, and no engraftment was detected in normal, nonanemic littermate control^.'^^^^ Only two previous studies have focused on engraftment in nondefective mice. In one in which adult bone marrow was the source of HSC," only transient (less than 6 weeks) engraftment in a small percent of animals (5.2%) was observed. In the other study in which rat fetal liver was the source," no engraftment was detected in the peripheral blood or bone marrow, and only a low degree of engraftment was found in thymus in 2 of 23 recipients at 4 weeks of age. These poor results can be explained by strain differences, injection techniques, and the methods used to detect engraftment (ie, GP1 isoenzymes and phenotyping, which can detect donor cells at a sensitivity of approximately I %).
In contrast, using the PCR assay, we found that 50% to 60% of nondefective recipients were durably engrafted. This is comparable with the engraftment rates observed previously in anemic, defective r n i~e . '~~. ' ' When we evaluated peripheral blood alone, as many as half the congenic recipients had donor cells present up to 20 weeks of age. The presence of these short-lived circulating cells probably does not represent permanent engraftment," as only a small number of recipients had detectable circulating donor cells beyond 20 weeks of age, with no significant difference between the allogeneic and congenic animals (8% v 25%, respectively; P > .08). When liver, spleen, and bone marrow were included in the analysis, the combined engraftment rate was 5 1 % in allogeneic and 62% in congenic recipients (P > 3 ) .
Interestingly, seven of eight allogeneic recipients had donor cells present in the bone marrow, suggesting a relatively high engraftment rate, even in nonanemic recipients. Of particular importance is our finding that engraftment rates in allogeneic and congenic recipients were quite similar. This suggests that MHC is not as important a determinant of engraftment efficiency at early gestational ages as was previously believed: an observation that has potentially important clinical implications with respect to available sources of matched versus mismatched donor cells.
Although the rate of engraftment in this nondefective mouse model was high and comparable with that previously obtained in W" and W4' anemic mice,'-9.'' the degree of engraftment (ie, percent of donor cells) was low (usually below 0.01 %) in both the allogeneic and congenic recipients, even considering the fact that our assay underestimated the percent of donor cells by approximately 50% (detection of male cells only). The apparently higher degree of engraftment demonstrated in anemic mice reflects the preferential expression of normal donor cells, although in one study of W' mice in which human donor cells were used, the frequency of detected human cells in the recipient tissues was lo-' to 10-4.'0 Possible approaches to increasing the percent donor cells are to inject larger numbers of stem cells in utero and/or to perform repeated postnatal injections or boosts. In our study we injected 5 X 10' fetal liver cells into each fetus, which is the maximal number that can practically be used in this model due to the size of the fetal recipient. Based on the report of Ikuta and W e i s~m a n , '~ approximately 0.025% of 15-day-old fetal liver cells are putative HSC, although the percent of c-kit-positive cells is considerably higher.IX This suggests, that we may have injected as few as 125 pluripotent HSC into each fetus, which is only slightly higher than what is necessary to engraft 50% of lethally irradiated adult congenic recipients," and much less than what is needed when allogeneic donor cells are used. Enrichment of stem cells and injection of higher numbers in utero is one approach that needs to be evaluated to increase the percent donor cells in nonanemic recipients. Another approach involves the use of postnatal boosts. Recently, Stewart et alZo showed that when sufficiently large numbers of congenic donor cells are injected into healthy adult recipients, the need for niches or space could be overcome without the need for pretransplant conditioning. When we injected lo6 MHC-mismatched donor cells into a tolerant mouse at 44 postnatal weeks, we observed a 25-fold increase in the percent donor cells in the peripheral blood 6 months post-boost. Intolerant, nonengrafted, and control mice similarly treated had no detectable circulating donor cells up to 9 months post-boost. It is possible that repeated injections of higher numbers of donor cells For personal use only. on September 24, 2017. by guest www.bloodjournal.org From postnatally in animals made tolerant by early in utero transplantation will result in an even better expression of donor cells in the peripheral blood.
Tolerance has been evaluated in only a few of the murine models using nondefective mice. In the early study by Billingham et a]," exposure of rodent fetuses to allogeneic cells resulted in partial or complete tolerance for donor strain-specific skin grafts. However, the A and CBA strains used shared class I1 MHC determinants and differed only at class I MHC antigens." Only six animals were evaluated, and engraftment was not measured. Howson-Jan et a1" found that 2 of 10 grafted mice with transient (less than 6 weeks of age) presence of circulating donor cells permanently accepted donor skin grafts when tested at 2 months of age. However, engraftment was determined by measuring GP1 only, and it is possible that a small percent (less than 1%) of donor cells were present during the graft placement. We tested 22 allogeneic recipients and found that in chimeric recipients in which permanent tolerance was induced, circulating donor cells were present during the graft placement but did not appear to be necessary for the maintenance of tolerance. In addition, we correlated skin graft acceptance with the percent donor cells and the tissues in which donor cells had engrafted. Significantly, we have found that less than 1% (usually less than 0.01%) donor cells in recipient blood or tissues is sufficient for tolerance induction, and even smaller numbers of donor cells can maintain tolerance. This is true even if one adjusts for the estimated 50% female donor cells present in the pooled fetal livers. Furthermore, none of the recipients with prolonged graft acceptance had donor cells present at any time in the blood. Durable engraftment in the spleen or the liver only was sufficient for induction of prolonged tolerance and the maintenance of permanent tolerance. Interestingly, eight of nine recipients who had prolonged or permanent graft acceptance showed durable engraftment in the liver. This could simply represent the fact that the liver was the most common engrafted site in the allogeneic group (other than bone marrow) or that there is a specific role of the liver in tolerance induction. This so-called hepatic tolerance has previously been sugg e~t e d " ,~~ and deserves further study, especially in the context of tolerance induction after in utero transplantation, as the liver is the major site of hematopoiesis in fetal life.
The main limitation of in utero HSC transplantation for the correction of various congenital disorders (in which there is no selective advantage for donor cell engraftment) is the very low degree of engraftment that occurs. We have shown that nondefective mice can readily engraft in utero with allogeneic MHC-mismatched HSC, albeit at a low degree. However, a very low percent of donor cells (0.01%) in the blood or the tissues permits development of tolerance to donor skin grafts, and donor cells in the peripheral blood do not appear to be necessary for graft maintenance. Finally, we have shown that the percent of circulating donor cells may significantly increase after a postnatal boost with even a small number of donor cells. Further studies addressing the optimal number of donor cells and timing of the boosts are required. This strategy in engrafted, tolerant animals may become a very powerful and effective approach for achieving an adequate donor cell population after in utero transplantation.
